↓ Skip to main content

Urinary Podocyte Excretion and Proteinuria in Patients Treated with Antivascular Endothelial Growth Factor Therapy for Solid Tumor Malignancies

Overview of attention for article published in Oncology (08909091), June 2014
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
5 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Urinary Podocyte Excretion and Proteinuria in Patients Treated with Antivascular Endothelial Growth Factor Therapy for Solid Tumor Malignancies
Published in
Oncology (08909091), June 2014
DOI 10.1159/000360180
Pubmed ID
Authors

Suzanne R. Hayman, Juan C. Calle, Aminah Jatoi, Iasmina M. Craici, Steven J. Wagner, Amy L. Weaver, Eddie L. Greene, Joseph P. Grande, Vesna D. Garovic

Abstract

Background: Urinary podocyte excretion (podocyturia) may function as a more specific marker of ongoing glomerular damage. This study sought to analyze the relationship between proteinuria and podocyturia in cancer patients treated with antivascular endothelial growth factor (anti-VEGF) agents. Methods: Thirty-seven patients treated with anti-VEGF medications were analyzed in a single-institution, cross-sectional study. Podocyte cultures were performed on random urine collections (50-100 ml), and podocytes were identified by positive podocin staining. The corresponding urine samples were analyzed for protein and creatinine (Cr) measurements. Results: Proteinuria ≥0.5 g/g Cr was found in 30% of the patients (median, 0.12; interquartile range, 0.04-0.86), and 62% had podocyturia. There was a significant difference in the amount of podocyturia between patients with proteinuria ≥0.5 g/g Cr and those with a value <0.5 g/g Cr (median podocyturia, 1.08 cells/mg Cr, range, 0-14.55 vs. 0.03 cells/mg Cr, range, 0-1.64, respectively; p < 0.001). A statistically significant correlation was observed between the cumulative dose of bevacizumab and both proteinuria (r = 0.48, p = 0.004) and podocyturia (r = 0.34, p = 0.045) as well as between proteinuria and podocyturia (r = 0.63, p < 0.001), suggesting that these are mechanistically related. Discussion: Ongoing podocyte loss may be mechanistically related to the onset and severity of proteinuria in patients treated with anti-VEGF agents. © 2014 S. Karger AG, Basel.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 5 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 5 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 2 40%
Student > Master 1 20%
Student > Ph. D. Student 1 20%
Professor 1 20%
Readers by discipline Count As %
Unspecified 2 40%
Medicine and Dentistry 2 40%
Computer Science 1 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 June 2014.
All research outputs
#9,949,926
of 12,429,094 outputs
Outputs from Oncology (08909091)
#802
of 1,197 outputs
Outputs of similar age
#129,089
of 192,248 outputs
Outputs of similar age from Oncology (08909091)
#6
of 40 outputs
Altmetric has tracked 12,429,094 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,197 research outputs from this source. They receive a mean Attention Score of 2.6. This one is in the 16th percentile – i.e., 16% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 192,248 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.